Delving into the Latest Updates on Adenosine Triphosphate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ATPace

Target

Purinergic P2 receptor

Action

agonists

Mechanism

Purinergic P2 receptor agonists

Therapeutic Areas

Cardiovascular DiseasesNervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Alzheimer DiseaseBradycardiaCachexia+ [2]

Originator Organization

Cordex AG

Active Organization-

Inactive Organization

Cordex AG

DSM Biomedical, Inc.

University of Pennsylvania

+ [3]

License Organization

Daiichi Sankyo Co., Ltd.

Alfresa Pharma Corp.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H16N5O13P3

InChIKeyZKHQWZAMYRWXGA-KQYNXXCUSA-N

CAS Registry56-65-5

Oxalic acid (OA), an essential pathogenic factor, has been identified in several plant pathogens, and researchers are currently pursuing studies on interference with OA metabolism as a treatment for related diseases. However, the metabolic route in Magnaporthe oryzae remains unknown. In this study, we describe D-erythroascorbic acid-mediated OA synthesis and its metabolic and clearance pathways in rice blast fungus. By knocking out the D-arabino-1,4-lactone oxidase gene (Moalo1), one-third of oxalic acid remained in M. oryzae, indicating a main pathway for oxalic acid production. M. oryzae OxdC (MoOxdC) is an oxalate decarboxylase that appears to play a role in relieving oxalic acid toxicity. Loss of Mooxdc does not affect mycelial growth, conidiophore development, or appressorium formation in M. oryzae; however, the antioxidant and pathogenic abilities of the mutant were enhanced. This is owing to Mooxdc deletion upregulated a series of OA metabolic genes, including the oxalate oxidase gene (Mooxo) and Moalo1, as well as both OA transporter genes. Simultaneously, as feedback to the tricarboxylic acid (TCA) cycle, the decrease of formic acid in ΔMooxdc leads to the reduction of acetyl-CoA content, and two genes involved in the β-oxidation of fatty acids were also upregulated, which enhanced the fatty acid metabolism of the ΔMooxdc. Overall, this work reveals the role of OA in M. oryzae. We found that OA metabolism was mainly involved in the growth and development of M. oryzae, OA as a byproduct of D-erythroascorbic acid after removing H₂O₂, the OA-associated pathway ensures the TCA process and ATP supply.

31 Dec 2025·Virulence

The sulfur-related metabolic status of Aspergillus fumigatus during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target

Article

Author: Amich, Jorge ; Storer, Isabelle ; Alharthi, Reem ; Al-Shidhani, Reem ; Zhao, Can ; Fortune-Grant, Rachael ; Tabernero, Lydia ; Bromley, Michael ; Sueiro-Olivares, Monica ; Bignell, Elaine ; Bin Shuraym, Hajer ; Scott, Jennifer

Sulfur metabolism is an essential aspect of fungal physiology and pathogenicity. Fungal sulfur metabolism comprises anabolic and catabolic routes that are not well conserved in mammals, therefore is considered a promising source of prospective novel antifungal targets. To gain insight into Aspergillus fumigatus sulfur-related metabolism during infection, we used a NanoString custom nCounter-TagSet and compared the expression of 68 key metabolic genes in different murine models of invasive pulmonary aspergillosis, at 3 time-points, and under a variety of in vitro conditions. We identified a set of 15 genes that were consistently expressed at higher levels in vivo than in vitro, suggesting that they may be particularly relevant for intrapulmonary growth and thus constitute promising drug targets. Indeed, the role of 5 of the 15 genes has previously been empirically validated, supporting the likelihood that the remaining candidates are relevant. In addition, the analysis of gene expression dynamics at early (16 h), mid (24 h), and late (72 h) time-points uncovered potential disease initiation and progression factors. We further characterized one of the identified genes, encoding the cytosolic serine hydroxymethyltransferase ShmB, and demonstrated that it is an essential gene of A. fumigatus, also required for virulence in a murine model of established pulmonary infection. We further showed that the structure of the ligand-binding pocket of the fungal enzyme differs significantly from its human counterpart, suggesting that specific inhibitors can be designed. Therefore, in vivo transcriptomics is a powerful tool for identifying genes crucial for fungal pathogenicity that may encode promising antifungal target candidates.

31 Dec 2025·Virulence

Guanosine enhances the bactericidal effect of ceftiofur sodium on Streptococcus suis by activating bacterial metabolism

Article

Author: Zhang, Zhiyun ; Cao, Mingyu ; Liu, Yanyan ; Qu, Qianwei ; Dong, Chunliu ; Dong, Yue ; Liu, Xiaona ; Wu, Haojie ; Xiong, Shanshan ; Zhao, Mengmeng ; Chen, Long ; Li, Yanhua ; Zheng, Yadan

The emergence and rapid development of antibiotic resistance poses a serious threat to global public health. Streptococcus suis (S. suis) is an important zoonotic pathogen, and the development of its antibiotic resistance has made the infections difficult to treat. The combination of non-antibiotic compounds with antibiotics is considered a promising strategy against multidrug-resistant bacteria. However, the mechanism by which metabolites act as antibiotic adjuvant remains unclear. Here, we found that guanosine metabolism was repressed in multidrug-resistant S. suis. Exogenous guanosine promoted the antibacterial effects of ceftiofur sodium (CEF) in vitro and in vivo. Furthermore, we demonstrated that exogenous guanosine promoted the biosynthesis of purine pathway, TCA cycle and bacterial respiration, which make bacteria more sensitive to the killing effect of antibacterial. In addition, the function of the cell membrane is affected by guanosine and the accumulation of antimicrobials in the bacteria increased. Bacterial-oxidative stress and DNA damage induced by guanosine is also one of the mechanisms by which the antibacterial effect is enhanced. These results suggest that guanosine is a promising adjuvant for antibacterial drugs and provide new theoretical basis for the clinical treatment of S. suis infection.

1

News (Medical) associated with Adenosine Triphosphate

30 Apr 2025

·pharma.economictimes.indiatimes.com

AstraZeneca to scrap trails of Truqap in prostate cancer after interim analysis

Cambridge: UK-pharma major AstraZeneca has announced plans of discontinuing the Phase III trial of its oncology asset Truqap (capivasertib) in prostate cancer , following an interim analysis suggesting that the “drug is unlikely to meet the dual primary endpoints.” As per the information shared by the company, the decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which reviewed data from a pre-specified interim analysis and concluded that the Truqap combination was unlikely to meet the dual primary endpoints— radiographic progression-free survival (rPFS) and overall survival– versus the comparator arm. The drug is being evaluated in the CAPItello-280 Phase III trial in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer . (mCRPC). The Phase III global trial enrolled 1,033 adult patients and the dual primary endpoints of the trial are radiographic progression-free survival (rPFS) and overall survival to be assessed by the investigator and over trial population respectively. As per the company the safety profile for Truqap was consistent with previous trials and will work with investigators to ensure the necessary follow-up with patients. Truqap is a adenosine triphosphate (ATP)-competitive inhibitor approved in the US, EU, Japan, China and several other countries for the treatment of adult patients with HR-positive (or estrogen receptor-positive). In 2024, the drug global sales reported a jump of 10x to $430 million (around ₹370 crore) attributed with the uptake in biomarker altered subgroup of the indication and some benefit in the US in Q4 2024 due to one-off launch stocking of blister pack. By Online Bureau ,

Phase 3Clinical Trial Termination

100 Deals associated with Adenosine Triphosphate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00171

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tachycardia	Phase 3	-	DSM Biomedical, Inc.	-
Tachycardia	Phase 3	-	University of Pennsylvania	-
Tachycardia	Phase 3	-	Pfizer Inc.	-
Tachycardia	Phase 3	-	Cordex AG	-
Alzheimer Disease	Phase 2	Spain	-	01 Dec 2014
Bradycardia	Phase 2	United States	Cordex Pharma, Inc.	-
Bradycardia	Phase 2	Canada	Cordex Pharma, Inc.	-
Bradycardia	Phase 2	-	University of Pennsylvania	-
Bradycardia	Phase 2	-	DSM Biomedical, Inc.	-
Bradycardia	Phase 2	-	Cordex AG	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2019	Not Applicable	-	119	Intravenous ATP infusion	fxuqyeocmi(mrdzqtkqiy) = ylmsvzkyss qlcpdgqigp (aplczzxxwd ) View more	-	03 Sep 2019
				Additional intracoronary papaverine administration	fxuqyeocmi(mrdzqtkqiy) = hfzdegdlsl qlcpdgqigp (aplczzxxwd ) View more
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	-	-	oATP	horuflwwuu(ysbkuuundd) = uydwrncemk ugscxmxvdu (rfijadaykk ) View more	Positive	01 Jul 2019
				Control (sterile saline)	horuflwwuu(ysbkuuundd) = tgjdwqgvgu ugscxmxvdu (rfijadaykk ) View more